Updated:
ORAGENICS INC
ORAGENICS INC, a Florida-domiciled biotech, has historically focused on developing oral vaccines and antibiotics using its proprietary genetically modified...
ORAGENICS INC
ORAGENICS INC, a Florida-domiciled biotech, has historically focused on developing oral vaccines and antibiotics using its proprietary genetically modified bacterial platform. The firm's pipeline centered on lantibiotics — a class of peptide antibiotics — and a protective antigen-based anthrax vaccine administered via an oral rinse, bypassing traditional intramuscular injection. The company's primary strategy was government-contract biodefense, directly targeting the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) stockpile. Its lead program, a recombinant protective antigen anthrax vaccine, progressed through Phase I clinical trials in the early 2010s, competing against the then-dominant BioThrax from Emergent BioSolutions. The firm also explored lantibiotic compounds targeting Clostridium difficile infections. Public filings show the firm operated with a lean research team, strategically filing patents covering oral mucosal immunization delivery methods. The company underwent a formal reverse merger in 2012, absorbing a dental probiotics entity which shifted its near-term commercial focus toward oral-care consumer products while clinical development programs continued amid constrained capital-raising efforts characteristic of small-cap life sciences firms (per SEC filings, 2012–2019). ORAGENICS' structural posture was that of a platform technology play rather than a single-asset biotech, attempting to leverage the same oral-delivery mechanism across biodefense, antibiotics, and consumer probiotics — a breadth ambition rarely sustained at its market capitalization range.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What was ORAGENICS INC's core vaccine technology?
Oragenics developed a mucosal anthrax vaccine based on protective antigen delivered via an oral rinse. The approach aimed to induce both systemic and mucosal immunity without needles, using recombinant protein expression technology. This differentiated it from the intramuscular BioThrax vaccine produced by Emergent BioSolutions.
Does ORAGENICS compete directly with Emergent BioSolutions?
ORAGENICS historically competed for a portion of the US biodefense countermeasure procurement budget, specifically the Strategic National Stockpile anthrax vaccine contract. While Emergent BioSolutions secured the dominant position with BioThrax, ORAGENICS positioned its oral vaccine as a logistical improvement for mass civilian prophylaxis scenarios.
What lantibiotic programs did the firm pursue?
ORAGENICS advanced lantibiotic compounds — peptide-based antibiotics produced by genetically modified bacteria — targeting Clostridium difficile and other gram-positive pathogens. The firm's MU1140 compound was a lead candidate. These programs were preclinical and intended to address antibiotic-resistant infections.
Did ORAGENICS undergo a corporate restructuring?
Yes. In 2012 ORAGENICS completed a reverse merger with a dental probiotics company, shifting near-term focus to over-the-counter oral-care products under brand channels. The anthrax vaccine and lantibiotic programs continued but operated within a meaningfully constrained R&D budget while the consumer division sought near-term revenue.
What government agency funded ORAGENICS' vaccine work?
ORAGENICS sought funding and procurement commitments from the Biomedical Advanced Research and Development Authority (BARDA), housed within the U.S. Department of Health and Human Services. BARDA is the primary civilian body funding medical countermeasures against chemical, biological, radiological, and nuclear threats.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: